Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Krepler, K; Wagner, J; Sacu, S; Wedrich, A.
The effect of intravitreal triamcinolone on diabetic macular oedema.
GRAEF ARCH CLIN EXP OPHTHAL 2005 243: 478-481.
Doi: 10.1007/s00417-004-1059-8
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Wedrich Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Diabetic macular oedema is a frequent cause of visual loss in patients with diabetic retinopathy. The purpose of this study was to assess the efficacy of intravitreal triamcinolone acetonide in reducing diabetic macular oedema and improving visual acuity. METHODS: In this prospective study 12 eyes of 12 patients with diabetic macular oedema unresponsive to prior laser treatment received an intravitreal injection of 4 mg triamcinolone acetonide. Examinations were performed 1 day preoperatively and at 1 week and 1, 3, 6, and 9 months after surgery and included slit-lamp examination, measurement of IOP, assessment of distance as well as reading visual acuity and assessment of macular thickness using optical coherence tomography (OCT). RESULTS: Mean age of the patients (mean+/-SD) was 66.6+/-8.6 years. Mean best-corrected visual acuity (BCVA) for distance (LogMAR using ETDRS charts) improved from 1.0+/-0.4 preoperatively to 0.9+/-0.4 (p=0.01) 1 week and to 0.9+/-0.4 (p=0.02) 1 month postoperatively. Mean BCVA for reading vision (LogRAD using Radner Reading Charts) improved from 1.1+/-0.4 preoperatively to 0.9+/-0.4 (p=0.002) 1 month postoperatively. Mean macular thickness decreased from 450+/-190 (microm) preoperatively to 305+/-153 (p=0.02) 1 month postoperatively. No significant improvement in VA and no significant reduction of macular thickness could be observed 3, 6, and 9 months postoperatively. Mean intraocular pressure significantly increased from 14.7+/-2.7 mmHg preoperatively to 16.9+/-3.0 mmHg at 1 month (p=0.02). CONCLUSION: A single intravitreal injection of triamcinolone acetonide led to a significant improvement in mean VA in patients with diabetic macular oedema. However, the significant effect was not permanent and persisted for only 1 month.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Diabetic Retinopathy - drug therapy
- Female - drug therapy
- Glucocorticoids - therapeutic use
- Humans - therapeutic use
- Injections - therapeutic use
- Intraocular Pressure - therapeutic use
- Macular Edema, Cystoid - drug therapy
- Male - drug therapy
- Prospective Studies - drug therapy
- Tomography, Optical Coherence - drug therapy
- Triamcinolone Acetonide - therapeutic use
- Visual Acuity - therapeutic use
- Vitreous Body - therapeutic use